Dalfampridine (Ampyra®) is an oral medication, in tablet form, which blocks tiny pores, or potassium channels, on the surface of nerve fibers. Blocking potassium channels may improve the conduction of nerve signals in along nerve fibers whose insulating myelin coating has been damaged by MS.
Dalfampridine is approved by the U.S. Food and Drug Administration (FDA) to improve walking in patients with multiple sclerosis, as demonstrated by an increase in walking speed.
Click here to read the Ampyra Prescribing Information for healthcare professionals.
Click here to read the Ampyra Medication Guide for patients.
For information about Ampyra and Acorda's support program, call 888-881-1918.
Financial Assistance Program
Ampyra Patient Support Services